Stock Track | Hims & Hers Health Soars 9.45% in Pre-market After Launching $49 Wegovy Pill Copy

Stock Track

Feb 05

Hims & Hers Health Inc. (HIMS) experienced a significant pre-market surge of 9.45% on Thursday, as the telehealth company announced a major expansion of its weight loss portfolio.

The stock movement follows the company's announcement that it will begin offering compounded copies of Novo Nordisk's Wegovy weight-loss pill at an introductory price of $49 per month. This represents a substantial discount compared to the approximately $199 charged by Novo Nordisk for the branded version. Following an initial payment, patients with a five-month subscription will pay $99 per month thereafter.

The compounded product uses the same active ingredient, semaglutide, as Novo's Wegovy but employs a different formulation and delivery system than FDA-approved oral semaglutide. Hims & Hers has doubled its facility footprint in 2025, which the company says enables it to provide treatments at more accessible price points, creating new competitive dynamics in the lucrative weight-loss drug market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1127086469"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1127086469\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1127086469?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127086469","market":"hk","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 9.45% in Pre-market After Launching $49 Wegovy Pill Copy","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) experienced a significant pre-market surge of 9.45% on Thursday, as the telehealth company announced a major expansion of its weight loss portfolio.</p><p>The stock movement follows the company's announcement that it will begin offering compounded copies of Novo Nordisk's Wegovy weight-loss pill at an introductory price of $49 per month. This represents a substantial discount compared to the approximately $199 charged by Novo Nordisk for the branded version. Following an initial payment, patients with a five-month subscription will pay $99 per month thereafter.</p><p>The compounded product uses the same active ingredient, semaglutide, as Novo's Wegovy but employs a different formulation and delivery system than FDA-approved oral semaglutide. Hims & Hers has doubled its facility footprint in 2025, which the company says enables it to provide treatments at more accessible price points, creating new competitive dynamics in the lucrative weight-loss drug market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 9.45% in Pre-market After Launching $49 Wegovy Pill Copy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 9.45% in Pre-market After Launching $49 Wegovy Pill Copy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-05 22:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) experienced a significant pre-market surge of 9.45% on Thursday, as the telehealth company announced a major expansion of its weight loss portfolio.</p><p>The stock movement follows the company's announcement that it will begin offering compounded copies of Novo Nordisk's Wegovy weight-loss pill at an introductory price of $49 per month. This represents a substantial discount compared to the approximately $199 charged by Novo Nordisk for the branded version. Following an initial payment, patients with a five-month subscription will pay $99 per month thereafter.</p><p>The compounded product uses the same active ingredient, semaglutide, as Novo's Wegovy but employs a different formulation and delivery system than FDA-approved oral semaglutide. Hims & Hers has doubled its facility footprint in 2025, which the company says enables it to provide treatments at more accessible price points, creating new competitive dynamics in the lucrative weight-loss drug market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1127086469","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127086469","pubTimestamp":1770301963,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) experienced a significant pre-market surge of 9.45% on Thursday, as the telehealth company announced a major expansion of its weight loss portfolio.The stock movement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票追踪|Hims&Hers Health在推出49美元Wegovy药丸副本后盘前飙升9.45%","themeId":"c1153e9c0a8e9571f0041cca121599eb","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) experienced a significant pre-market surge of 9.45% on Thursday, as the telehealth company announced a major expansion of its weight loss portfolio.The stock movement follows the company's announcement that it will begin offering compounded copies of Novo Nordisk's Wegovy weight-loss pill at an introductory price of $49 per month. This represents a substantial discount compared to the approximately $199 charged by Novo Nordisk for the branded version. Following an initial payment, patients with a five-month subscription will pay $99 per month thereafter.The compounded product uses the same active ingredient, semaglutide, as Novo's Wegovy but employs a different formulation and delivery system than FDA-approved oral semaglutide. Hims & Hers has doubled its facility footprint in 2025, which the company says enables it to provide treatments at more accessible price points, creating new competitive dynamics in the lucrative weight-loss drug market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}